PMID- 12515857 OWN - NLM STAT- MEDLINE DCOM- 20030224 LR - 20220317 IS - 0027-8424 (Print) IS - 1091-6490 (Electronic) IS - 0027-8424 (Linking) VI - 100 IP - 2 DP - 2003 Jan 21 TI - A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. PG - 639-44 AB - Epidermal growth factor receptor (EGFR) has attracted considerable attention as a target for cancer therapy. Wild-type (wt)EGFR is amplified/overexpressed in a number of tumor types, and several mutant forms of the coding gene have been found, with DeltaEGFR, a deletion mutation lacking exons 2-7 of the external domain, being the most common and particularly associated with glioblastoma. We generated monoclonal antibodies (mAbs) against NR6(DeltaEGFR) (mouse fibroblast line NR6 transfected with DeltaEGFR). mAb 806 with selective reactivity for NR6(DeltaEGFR) in mixed hemadsorption assays, fluorescence-activated cell sorting, Western blot, and immunohistochemistry was analyzed in detail and compared with mAbs 528 (anti-wtEGFR) and DH8.3 (anti-DeltaEGFR). In xenograft tumors and molecularly pretyped glioblastomas, the reactivity pattern was as follows: 528 reactive with amplified and nonamplified wtEGFR; DH8.3 reactive with DeltaEGFR; and 806 reactive with amplified/overexpressed wtEGFR (with or without DeltaEGFR). In normal tissues, 528 but not DH8.3 or 806 was widely reactive with many organs, e.g., liver expressing high EGFR levels. In glioblastoma and non-CNS tumor panels, 806 was reactive with a high proportion of glioblastomas and a substantial number of epithelial cancers of lung and of head and neck. DH8.3 reactivity was restricted to DeltaEGFR-positive glioblastoma. Thus, 806 represents a category of mAbs that recognizes tumors with EGFR amplification/overexpression but not normal tissues or tumors with normal EGFR levels. Our study also indicates that DeltaEGFR is restricted to glioblastoma, in contrast to other reports that this mutation is found in tumors outside the brain. FAU - Jungbluth, Achim A AU - Jungbluth AA AD - Ludwig Institute for Cancer Research, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA. jungblua@mskcc.org FAU - Stockert, Elisabeth AU - Stockert E FAU - Huang, H J Su AU - Huang HJ FAU - Collins, Vincent P AU - Collins VP FAU - Coplan, Keren AU - Coplan K FAU - Iversen, Kristin AU - Iversen K FAU - Kolb, Denise AU - Kolb D FAU - Johns, Terrance J AU - Johns TJ FAU - Scott, Andrew M AU - Scott AM FAU - Gullick, William J AU - Gullick WJ FAU - Ritter, Gerd AU - Ritter G FAU - Cohen, Leonard AU - Cohen L FAU - Scanlan, Matthew J AU - Scanlan MJ FAU - Cavenee, Webster K AU - Cavenee WK FAU - Old, Lloyd J AU - Old LJ LA - eng PT - Journal Article DEP - 20030106 PL - United States TA - Proc Natl Acad Sci U S A JT - Proceedings of the National Academy of Sciences of the United States of America JID - 7505876 RN - 0 (Antibodies, Monoclonal) RN - EC 2.7.10.1 (ErbB Receptors) SB - IM EIN - Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):2163. Cavanee, Webster K [corrected to Cavenee, Webster K] MH - Animals MH - Antibodies, Monoclonal/*therapeutic use MH - ErbB Receptors/analysis/*genetics/*immunology MH - Glioblastoma/chemistry/therapy MH - Humans MH - Mice MH - Mice, Inbred BALB C MH - Neoplasm Transplantation MH - Neoplasms/chemistry/*therapy MH - Transplantation, Heterologous MH - Tumor Cells, Cultured PMC - PMC141049 EDAT- 2003/01/08 04:00 MHDA- 2003/02/25 04:00 PMCR- 2003/07/21 CRDT- 2003/01/08 04:00 PHST- 2003/01/08 04:00 [pubmed] PHST- 2003/02/25 04:00 [medline] PHST- 2003/01/08 04:00 [entrez] PHST- 2003/07/21 00:00 [pmc-release] AID - 232686499 [pii] AID - 6864 [pii] AID - 10.1073/pnas.232686499 [doi] PST - ppublish SO - Proc Natl Acad Sci U S A. 2003 Jan 21;100(2):639-44. doi: 10.1073/pnas.232686499. Epub 2003 Jan 6.